Slide 1: Investor Presentation Full Year 2026 Results
For personal use only Investor Presentation Full Year 2026 Results August 2026 Treatment focused. Technology driven.
Slide 2: Disclaimer
Disclaimer This document has been prepared as a summary only and does not contain all information about SomnoMed Limited’s (the Company’s) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document
Slide 3: Company Highlights
For personal use only Company Highlights
Slide 4: SomnoMed is the global market leader in oral appliance therapy
SomnoMed is the global market leader in oral appliance therapy With over 1 million patients treated worldwide and leading positions across multiple geographies, SomnoMed is well positioned to capitalise on the market opportunity and drive growth For personal use only VISION LARGE AND GROWING MARKET
Slide 5: Financial Highlights
Financial Highlights Strong foundation established to deliver on strategic initiatives For personal use only Solid Financial Results Disciplined Cost / Capital Robust Balance (FY26) Management Sheet • EBITDA1 - Up 19% to $10.9m, • FY26 cost discipline • Positive operating cash flow 9.6% margin contr
Slide 6: Operational Highlights
Operational Highlights Strong foundation established to deliver on strategic initiatives For personal use only Experienced Leadership Production Improvements Product Innovation (Virtus) Executive management update Manufacturing capacity ~50%1 of OSA patients have co- for FY26 and FY27 to date: e
Slide 7: FY2026 Results
For personal use only FY2026 Results
Slide 8: Financial Highlights
Financial Highlights Revenue growth EBITDA1 growth Positive operating cash flow after leases +3% +19% For personal use only +8% $114.5m $5.2m $111.5m $10.9m 9.6% margin $4.8m $9.2m 8.2% margin FY25 FY26 FY25 FY26 FY25 FY26 • 1HFY revenue (up 13% and 8% • EBITDA1 and margin improvement • Increase in
Slide 9: Regional Revenue Highlights
Regional Revenue Highlights Europe North America APAC +1% For personal use only $61m $62m +6% +17% -13% $46m $43m $33m $33m +11% +1% $28m $29m -3% $24m $22m $21m $21m -4% -1% $7m $7m $4m $4m $3m $3m 1H 2H FY 1H 2H FY 1H 2H FY FY25 FY26 FY25 FY26 FY25 FY26 © August 2026 SomnoMed 9 +8% -9% -1% +10% +1
Slide 10: Profit or Loss Summary
Profit or Loss Summary $m FY26 FY25 % Revenue 114.5 111.5 +3% Gross profit 70.0 66.7 +5% For personal use only Sales and marketing expenses (23.0) (22.9) +0% Administrative and other expenses (19.0) (18.4) +3% Operating profit 28.1 25.4 +10% Corporate, research and business (17.1) (16.2) +5% develop
Slide 11: Balance Sheet Summary
Balance Sheet Summary $m 30 June 2026 30 June 2025 Cash and cash equivalents 17.2 17.3 For personal use only Trade and other receivables 14.5 18.5 Inventories 7.4 7.4 Property, plant and equipment 7.6 7.0 Intangible assets 22.4 21.5 Working capital Right of use asset 4.7 6.9 • Improvement in collect
Slide 12: Cash Flow Summary
Cash Flow Summary $m FY26 FY25 EBITDA1 10.9 9.2 Movement in working capital and other non-cash (0.4) (0.1) (1.4) (0.8) One-off expenses For personal use only Tax paid One-off expenses (0.9) (0.5) • Related to cash settlement of prior year and Operating cash flow (before leases) 8.3 7.8 current year
Slide 13: Strategy and Outlook
For personal use only Strategy and Outlook
Slide 14: Market Dynamics
Market Dynamics CPAP failures: up to 50% of patients discontinue therapy1 For personal use only OAT competitors: growth in lower cost products & clinical differentiation challenges Pharma entrants: GLP-1s / emerging drugs are driving patient growth Neurostimulation: newer, high-cost, invasive surgic
Slide 15: From Turnaround to Sustainable Growth
From Turnaround to Sustainable Growth FY24 - FY26 FY27 - FY30 For personal use only Financial & Operational Turnaround Growth & Profitability Objectives Financial: cleared debt, generated Return to double digit revenue growth positive cashflow Progressively expand EBITDA1 People and culture:
Slide 16: Market-Leading Portfolio Tailored by Region
Market-Leading Portfolio Tailored by Region For personal use only Flex & Fusion® Herbst Advance Elite® Virtus Established European Platforms Designed for US Reimbursement Next-Generation OAT Innovation Reimbursed across Key European Markets Medicare Reimbursed Global Controlled Release Underway © Au
Slide 17: Commercial Focus to Drive Growth
Commercial Focus to Drive Growth For personal use only North America Europe APAC • Product innovation targeting • Restructured commercial and • Continued engagement with most accessible Centre for operational leadership to GLP-1 manufacturer Medicare and Medicaid improve customer experience Services
Slide 18: A Bold Vision to Drive Growth FY27 & Beyond
A Bold Vision to Drive Growth FY27 & Beyond Strategic roadmap to be detailed at the upcoming Annual General Meeting. For personal use only 1. Capture the Growing 2. Accelerate New Products 3. Expand Referring and Patient Pool Aligned to Market Needs Treating Clinicians • GLP-1s and other pharma-led
Slide 19: FY27 – Outlook
FY27 – Outlook Setting the stage for growth For personal use only As announced on 27 July 2026, the Company is targeting high single digit revenue growth in FY27 while maintaining EBITDA1 margins consistent with FY26. FY27 guidance range is expected to be issued as part of the 2026 Annual General Me
Slide 20: Q&A
For personal use only Q&A
Slide 21: Thank You
For personal use only Thank You For further information please contact: Investor Relations: IR@somnomed.com.au © August 2026 SomnoMed 21